bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S6 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S6: Effect of single and dual blockade (DB) on apoptosis in resistant and parental cell lines. (A) Percentage of cells undergoing apoptosis and necrosis measured by flow cytometry: paired t-test statistics calculated for DB versus no treatment. (NT) (B) Representative confocal microscopy of cleaved caspase-3 (red), after 24 hours of treatment. Blue = DAPI (nuclei). (C) Cleaved caspase-3 immunofluorescence, mean intensity averaged from 4 experiments, with t-test statistics *P<0.05; **P<0.001; ***P<0.0001. (D) Relative migration rate, expressed as increasing percentage cell density across a monolayer wound over 44 hours, mean values from 3 experiments {plus minus} SEM. Treatments are control (black solid), erlotinib 10 ÂµM (E10- black dotted), NVP-AEW541 1 ÂµM (A1- black dashed), NVP-BYL719 5 ÂµM (B5- grey solid), E10A1 (E10+ A1- grey dotted), and E10B5 (E10+ B5- grey dashed). Proliferation was inhibited by 10 Âµg/ml mitomycin.
Supplementary Table 1 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Table 1. Patient details for A) Fresh Frozen test cohort and B) archival validation cohort
Supplementary Tables and Figures from The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Authors: Helsten Teresa , Elkin Sheryl , Arthur Elisa , Tomson Brett N. , Carter Jennifer , Kurzrock Razelle
Published: April 2023

Supplementary Table S1. Genes included in Foundation One assay. Supplementary Table S2. Frequencies of FGFR aberrations by histology for all histologies with {greater than or equal to} 75 cases analyzed Supplementary Table S3. Frequencies of FGFR aberrations by histology for all histologies with < 75 cases analyzed Supplementary Table S4. Summary of FGFR missense mutations and their functional significance Supplementary Table S5. Listing of all gene fusions in the data set (total = 28 cases) Table S6. Co-existent gene aberrations for all cases with FGFR aberrations Supplementary Figure S1. FGFR1 aberrations. Supplementary Figure S2. FGFR2 aberrations. Supplementary Figure S3. FGFR3 aberrations. Supplementary Figure S4. FGFR4 aberrations.
Supplementary Figure 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

BCMab1 antibody treatment promotes tumor-inside NK cell cytolysis.
Supplementary Figure 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

GALNT1 knockdown in LNCaP cells has no effect on attachment, transmigration, colony formation, and wound healing.
Table S1 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Table S1. MiSeq 57-gene panel list
Supplementary Tables S1-S3 from Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
Authors: Dowsett Mitch , Sestak Ivana , Buus Richard , Lopez-Knowles Elena , Mallon Elizabeth , Howell Anthony , Forbes John F. , Buzdar Aman , Cuzick Jack
Published: April 2023

Supplementary Table S1: Hazard Ratios (95% CI) and chi-square values for all recurrence and all individual genes and gene modules according to time periods in all patients, HER2-ve patients, and HER2-ve/Node-ve patients. Supplementary Table S2: Hazard Ratios (95% CI) and chi-square values for distant recurrence and all individual genes and gene modules according to time periods in all patients, HER2-ve patients, and HER2-ve/Node-ve patients. Supplementary Table S3: Comparison of GHI and IHC genes according to time period in all patients, HER2-ve, and HER2-ve/Node-ve patients.
Figures S1-12, Table 1 from BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Authors: Wang Tao , Xiao Min , Ge Yingbin , Krepler Clemens , Belser Eric , Lopez-Coral Alfonso , Xu Xiaowei , Zhang Gao , Azuma Rikka , Liu Qin , Liu Rui , Li Ling , Amaravadi Ravi K. , Xu Wei , Karakousis Giorgos , Gangadhar Tara C. , Schuchter Lynn M. , Lieu Melissa , Khare Sanika , Halloran Molly B. , Herlyn Meenhard , Kaufman Russel E.
Published: April 2023

Figures S1-12, Table 1. Figure S1: Macrophages confer melanoma cell resistance to PLX4720 and Dabrafenib. Figure S2: Macrophages activate MAPK signaling, but do not activate CRAF, ARAF, NF- κB, PDGFRβ and STAT3 signaling in melanoma cells. Figure S3: Effects of growth factors on melanoma cell growth in the presence of PLX4720. Figure S4: Effects of VEGF on BRAFi-induced growth inhibition and cell death. Figure S5: The effect of macrophages on expression of VEGF receptors in melanoma cells. Figure S6. Blockade of VEGF signaling with a VEGFR inhibitor, brivanib alaninate reverses macrophagemediated resistance to PLX4720. Figure S7: Blockade of VEGF signaling with an anti-VEGF antibody reverses macrophagemediated resistance to PLX4720. Figure S8: BRAF inhibition elicits potent effects in macrophages. Figure S9: Effects of combination therapy of PLX4720 and GW2580 on melanoma growth in a xenograft model. Figure S10: Targeting macrophages with a M-CSFR inhibitor, GW2580, has a modest effect on melanoma cell growth and cell death. Figure S11: Effects of GW2580 and/or PLX4720 on tumor angiogenesis and macrophage infiltration. Figure S12: Positive control for Ki67 and CD163 staining. Table 1. Summary of melanoma patient clinical information
Supplementary Tables from Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case–Control Study
Authors: Mendoza- Pérez Julia , Gu Jian , Herrera Luis A. , Tannir Nizar M. , Matin Surena F. , Karam Jose A. , Huang Maosheng , Chang David W. , Wood Christopher G. , Wu Xifeng
Published: April 2023

Global DNA methylation levels classified by tertiles of controls and estimates of RCC risk by tertiles of global DNA methylation stratified by host characteristics
Supplementary Methods, Tables S1 and S2, Figure Legend from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Authors: Kummar Shivaani , Oza Amit M. , Fleming Gini F. , Sullivan Daniel M. , Gandara David R. , Naughton Michael J. , Villalona-Calero Miguel A. , Morgan Robert J. , Szabo Peter M. , Youn Ahrim , Chen Alice P. , Ji Jiuping , Allen Deborah E. , Lih Chih-Jian , Mehaffey Michele G. , Walsh William D. , McGregor Paul M. , Steinberg Seth M. , Williams P. Mickey , Kinders Robert J. , Conley Barbara A. , Simon Richard M. , Doroshow James H.
Published: April 2023

Supplementary Methods, Tables S1 and S2, Figure Legend
Supplemental Figure 4 from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 4. PLK3 expression promotes apoptotic cell death in the setting of RB loss.
Figure S1 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Authors: Kummar Shivaani , Oza Amit M. , Fleming Gini F. , Sullivan Daniel M. , Gandara David R. , Naughton Michael J. , Villalona-Calero Miguel A. , Morgan Robert J. , Szabo Peter M. , Youn Ahrim , Chen Alice P. , Ji Jiuping , Allen Deborah E. , Lih Chih-Jian , Mehaffey Michele G. , Walsh William D. , McGregor Paul M. , Steinberg Seth M. , Williams P. Mickey , Kinders Robert J. , Conley Barbara A. , Simon Richard M. , Doroshow James H.
Published: April 2023

Supplemental Figure S1. Kaplan-Meier analysis of the progression free survival (PFS) of patients on each treatment arm stratified by BRCA status showed no significant differences.
Supplemental Figure 1 from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 1. RB status does not impinge on the alterations of cell cycle after radiation
Supplementary Figure 1, Tables 1 - 4 from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
Authors: Gaykema Sietske B.M. , Schröder Carolien P. , Vitfell-Rasmussen Joanna , Chua Sue , Oude Munnink Thijs H. , Brouwers Adrienne H. , Bongaerts Alfons H.H. , Akimov Mikhail , Fernandez-Ibarra Cristina , Lub-de Hooge Marjolijn N. , de Vries Elisabeth G.E. , Swanton Charles , Banerji Udai
Published: April 2023

Supplementary Figure 1. The arithmetic mean concentration-time profiles for AUY922 and BJP762. Supplementary Table 1. The most common adverse events of AUY922. Supplementary Table 2. Adverse events with CTCAE grades 3 and 4. Supplementary Table 3. The SUVmax of 89Zr-trastuzumab before and during treatment with AUY922. Supplementary Table 4. SUVmax of 89Zr-bevacizumab before and during treatment with AUY922.
Supplementary Figure S1 from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Supplementary Figure S1. Figure describing extended classification stability analyses for biased removal of proximal-proliferative or proximal-inflammatory classified tumors
Supplementary Table 1 from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Table 1. Tumorigenic potential of cells sorted from normoxic and hypoxic spheres of the six xenograft models (take rate in percentage)
Supplementary Methods, Supplementary Figures 1-5 from Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
Authors: Sameni Mansoureh , Tovar Elizabeth A. , Essenburg Curt J. , Chalasani Anita , Linklater Erik S. , Borgman Andrew , Cherba David M. , Anbalagan Arulselvi , Winn Mary E. , Graveel Carrie R. , Sloane Bonnie F.
Published: April 2023

Supplementary Methods; Figure S1: Immunoblot and immunofluorescence analysis of MET and HGF in TNBC and fibroblast cell lines. Figure S2: Met inhibition has minimal effect on ERK5 signaling in human TNBC cells. Figure S3: XL184 and U0126 significantly reduce volume and outgrowths of MDA-MB-231 structures. Figure S4: Minimal growth recovery is observed after XL184 removal Figure S5: MET inhibition in C3H-SCID mice.
Figure S1 from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

Figure S1. In the 6 models xenografted with human RCC, we identified 2 models responders to sunitinib and 4 non-responders. When treated with sunitinib, necrosis occurs earlier in the responder models
Supplementary Figures 1-6, Supplementary Tables 1-2 from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Authors: McCann Katy J. , Mander Ann , Cazaly Angelica , Chudley Lindsey , Stasakova Jana , Thirdborough Stephen M. , King Andrew , Lloyd-Evans Paul , Buxton Emily , Edwards Ceri , Halford Sarah , Bateman Andrew , O'Callaghan Ann , Clive Sally , Anthoney Alan , Jodrell Duncan I. , Weinschenk Toni , Simon Petra , Sahin Ugur , Thomas Gareth J. , Stevenson Freda K. , Ottensmeier Christian H.
Published: April 2023

Supplementary Figure S1: Detection of CAP-1-specific T-cells Supplementary Figure S2: Effect of CAP-1-specific responses on OS Supplementary Figure S3: Effect of tumor load on vaccine-induced responses Supplementary Figure S4: Discovery of CAP-1-specific TCRs Supplementary Figure S5: Effect of diarrhea on OS Supplementary Figure S6: Effect of diarrhea and CEA drops on OS Supplementary Table S1: MIATA Supplementary Table S2: CAP-1-specific TCRs
Supplemental Figure 2 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 2. A, KRAS G12C mutation is the most frequently mutated in smokers while G12D is most common in never-smokers. B and C, Never-smokers were significantly more likely than former or current smokers to have a transition mutation (G>A) rather than transversion mutations known to be smoking-related (G>T or G>C).
Supplementary Tables S1 and S2 from Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Authors: Vassilakopoulou Maria , Avgeris Margaritis , Velcheti Vamsidhar , Kotoula Vassiliki , Rampias Theodore , Chatzopoulos Kyriakos , Perisanidis Christos , Kontos Christos K. , Giotakis Aris I. , Scorilas Andreas , Rimm David , Sasaki Clarence , Fountzilas George , Psyrri Amanda
Published: April 2023

Supplemental Table 1. Correlation of TILs and PD-L1 with patients' clinicopathological features Supplemental Table 2. Cox proportional regression analysis for the prediction of Laryngeal SCC patients' DFS and OS according to PD-L1 mRNA levels
Supplemental Figure 1 from Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Authors: Vassilakopoulou Maria , Avgeris Margaritis , Velcheti Vamsidhar , Kotoula Vassiliki , Rampias Theodore , Chatzopoulos Kyriakos , Perisanidis Christos , Kontos Christos K. , Giotakis Aris I. , Scorilas Andreas , Rimm David , Sasaki Clarence , Fountzilas George , Psyrri Amanda
Published: April 2023

Supplemental Figure 1. Correlation of PD-L1 protein and mRNA expression levels, and %TILs percentage with laryngeal SCC patients clinicopathological features. Box plots representing the correlation of PD-L1 protein and mRNA expression and %TILs percentage with (a) tumor stage, (b) grade, (c) node status, (d) alcohol consumption, (e) smoking behavior, (f) gender and (e) age. The p values calculated by Mann-Whitney U test (a, c, d, f and g) and Jonckheere-Terpstra test (b and e).
Supp. Table 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplementary Table S1. KRAS mutant NSCLC patients' characteristics (n=514)
Supplementary Table 1 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Table 1. 10 OTUs with smallest P-values at genus and species levels. Comparisons are made between the 2 clusters using PAM clustering with JSD distance
Supplementary Figure 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Figure 2. Time on VEGF-TKI as it relates to (a) bacterial diversity as estimated by Shannon Index, (b) relative abundance of Bacteroides, and (c) relative abundance of Prevotella
Supplementary Methods from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Methods
Supplementary Figure S3 from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Figure S3. Inverse correlation between S phase accumulation of cells and gemcitabine IC50. Cells were treated with 10 nM gemcitabine for 24 h, prior to fixation in 70% ethanol and staining with propidium iodide. The proportion of cells in S phase was calculated using ModFit LT (Verity Software House).
Supplementary Figure S2 from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Authors: Wouters Maartje C.A. , Komdeur Fenne L. , Workel Hagma H. , Klip Harry G. , Plat Annechien , Kooi Neeltje M. , Wisman G. Bea A. , Mourits Marian J.E. , Arts Henriette J.G. , Oonk Maaike H.M. , Yigit Refika , de Jong Steven , Melief Cornelis J.M. , Hollema Harry , Duiker Evelien W. , Daemen Toos , de Bruyn Marco , Nijman Hans W.
Published: April 2023

Disease-specific survival (DSS) analyses by Kaplan Meier method of the primary surgery (PS) cohort for high and low infiltration of CD27+ cells. CD27 infiltration in the tumor epithelium is a prognostic factor in patients in which the surgical cytoreduction resulted in residual tissue of maximum 1 cm. Groups were created on basis of surgical outcome; red line shows patients that had no residual tumor after surgery, the violet lines depict patients that had residual tumors of {less than or equal to}1 cm, blue line represents patients with >1cm of residual tumor.
Supplementary Figure S1 from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Figure S1. Transfection efficiency of siRNA measured with fluorescence. 50 nM Block-iT fluorescent siRNA was transfected and cells fixed 6 h later.
Supplementary tables from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer patient cohorts with mature survival data in the Singapore dataset. Supplementary table 2. EphA2 and clinical-pathological correlates in CRC. Correlation between EphA2 and CD44, LGR5, CD133, Ki-67 and AXL in 509 stage I-IV CRC cases of the Singapore dataset. Supplementary table 3. Statistical associations between pairs of factors in the surgery only (A) and surgery/chemotherapy (B) stage II/III groups in the Singapore dataset. Supplementary table 4. A. Univariate and multivariate analysis (Cox proportional hazards regression) of resection-chemotherapy stage II/III patient group. B. Final multivariate model (Cox proportional hazards regression) of resection-chemotherapy stage II/III patient group. Supplementary table 5. Statistical association between expression levels of TGF-α and EphA2 using Spearman's Rank Correlation in GSE17536, GSE39582, GSE14333 and The Cancer Genome Atlas (TCGA). Within each dataset the value of Rho and associated p-value is reported.
Figure S4 from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

Figure S4. Impact of the absolute number of infused donor alloreactive NK cells on the probability of response.
Supplementary figure S2 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Role of p53, Src family kinases and RAS/MAPK pathway in regulating EphA2 expression levels.
Supplementary Methods from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Methods
Supplementary Figure 7 and 8 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Supplementary Figure 7:Detection of CD103 and s1p1 expression by HPV16 E7-specific CD8+ T cells after intracervicovaginal vaccination Supplementary Figure 8: Comparison of HPV16 E7-specific CD8+ T cells induced by pNGVL4a-Sig/E7(detox)/HSP70 intracervicovaginal vaccination followed by either intracervicovaginal or subcutaneous TA-HPV boost
Supplementary Figure 3 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Migration of CSFE-labeled α4β7 expressing E7-specific CD8+ T cells into spleen and vagina of WT or Itgb7-/- mice
Suppl Fig 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 1. GC Receptor expression and functionality in T- and B-ALL cell lines.
Supplementary Figure 3 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Relative changes (mean and standard deviation) in γ-H2AX expression in CD3+ (A) and CD14+ (B) cells and by microscopy (C) before and after treatment. Figure S2C shows representative images of γ-H2AX foci incidence in PBMCs from one patient pre-treatment (C1D1), cycle 1 day 2 (C1D2), cycle 1 day 3 (C1D3), and cycle 2 day 1 pre-treatment (C2D1). Green, γ-H2AX; red, DNA stained with propidium iodide.
Figure S1 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Body weight of mice as a percentage of their initial weight as a measure of systemic toxicity.
Tables S2-S4 from Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
Authors: Coghill Anna E. , Pfeiffer Ruth M. , Proietti Carla , Hsu Wan-Lun , Chien Yin-Chu , Lekieffre Lea , Krause Lutz , Teng Andy , Pablo Jocelyn , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Liu Zhiwei , Chen Chien-Jen , Middeldorp Jaap , Mulvenna Jason , Bethony Jeff , Hildesheim Allan , Doolan Denise L.
Published: April 2023

Supplemental Tables S2-S4: Antibody Responses against 199 EBV peptide sequences and risk of early-stage NPC in a cross-sectional study
Supplementary Table S1 from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Table S1. Clinical and molecular characteristics of a series of 242 patients with metastatic CRC.
Supplementary Figure S5 from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Figure S5. Immunohistochemical detection of SET expression in patients with metastatic colorectal cancer showing SET negative (A) and positive (B) stainings.
Supplementary Figure S1 from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Figure S1. SET is deregulated in CRC patients and induces proliferation and colonosphere formation in DLD-1, SW620 and HCT-116 cells.
supplemental legend from Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients
Authors: Parra Edwin R. , Behrens Carmen , Rodriguez-Canales Jaime , Lin Heather , Mino Barbara , Blando Jorge , Zhang Jianjun , Gibbons Don L. , Heymach John V. , Sepesi Boris , Swisher Stephen G. , Weissferdt Annikka , Kalhor Neda , Izzo Julie , Kadara Humam , Moran Cesar , Lee Jack J. , Wistuba Ignacio I.
Published: April 2023

supplemental legend
Supplementary Figures from Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Authors: Zumsteg Zachary S. , Morse Natasha , Krigsfeld Gabriel , Gupta Gaorav , Higginson Daniel S. , Lee Nancy Y. , Morris Luc , Ganly Ian , Shiao Stephan L. , Powell Simon N. , Chung Christine H. , Scaltriti Maurizio , Baselga José
Published: April 2023

Supplementary Figure S1. GDC-0032 downregulated PI3K signaling in a dose dependent fashion. Supplementary Figure S2. BYL719 enhances radiation induced cell death in PIK3CA activated cell lines. Supplementary Figure S3. A66 enhances radiation induced cell death in PIK3CA activated cell lines Supplementary Figure S4. PI3K pathway inhibition enhances cell death in HSC-2 (PIK3CA mutated) following irradiation. Cells were treated with the given drugs for 24 hours, irradiated with 4 Gy, then assessed for Annexin V staining 72 hours after irradiation. Supplementary Figure S5. GDC-0032 radiosensitizes LB-771 (PIK3CA amplified) cells in vitro as assessed via the clonogenic survival assay. Supplementary Figure S6. GDC-0032 enhances DNA damage and apoptosis following irradiation. Supplementary Figure S7. GDC-0032 does not significantly alter the early G2/M checkpoint. Supplementary Figure S8. ATR inhibition partially blocks the early G2/M checkpoint. Supplementary Figure S9. Wee1 inhibition partially blocks the early G2/M checkpoint. Supplementary Figure S10. Wee1 inhibition doesn't reverse the enhanced G2/M checkpoint induced by GDC-0032 following irradiation. 3 Supplementary Figure S11. GDC-0032 and radiation is superior to either treatment alone in an HPV(+) oropharyngeal squamous cell carcinoma patient derived xenograft.
Supplementary Table 1 from Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Authors: Alagesan Brinda , Contino Gianmarco , Guimaraes Alexander R. , Corcoran Ryan B. , Deshpande Vikram , Wojtkiewicz Gregory R. , Hezel Aram F. , Wong Kwok-Kin , Loda Massimo , Weissleder Ralph , Benes Cyril , Engelman Jeffrey A. , Bardeesy Nabeel
Published: April 2023

Supplementary Table 1. Excel spreadsheet showing results of drug screen indicating relative sensitivity of PDAC cell lines compared to non-PDA cell lines.
Supplemental Table 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Authors: Nilsson Monique B. , Giri Uma , Gudikote Jayanthi , Tang Ximing , Lu Wei , Tran Hai , Fan Youhong , Koo Andrew , Diao Lixia , Tong Pan , Wang Jing , Herbst Roy , Johnson Bruce E. , Ryan Andy , Webster Alan , Rowe Philip , Wistuba Ignacio I. , Heymach John V.
Published: April 2023

In the TCGA NSCLC dataset there was a significantly greater prevalence of p53 mutations in patients with KDR CNG compared to KDR CNG negative patients (p = 0.001).
Supplementary Tables 1-6 from Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
Authors: Lou Hong , Villagran Guillermo , Boland Joseph F. , Im Kate M. , Polo Sarita , Zhou Weiyin , Odey Ushie , Juárez-Torres Eligia , Medina-Martínez Ingrid , Roman-Basaure Edgar , Mitchell Jason , Roberson David , Sawitzke Julie , Garland Lisa , Rodríguez-Herrera Maria , Wells David , Troyer Jennifer , Pinto Francisco Castillo , Bass Sara , Zhang Xijun , Castillo Miriam , Gold Bert , Morales Hesler , Yeager Meredith , Berumen Jaime , Alvirez Enrique , Gharzouzi Eduardo , Dean Michael
Published: April 2023

Supplementary Tables 1-6. Supplemental Table 1. Primers used in Ion Torrent sequencing of HPV. Supplemental Table 2. Predicted somatic mutations in PIK3CA discovered by targeted sequencing of cervical tumors from Mexico, Venezuela, and Guatemala. Supplementary Table 3. Predicted somatic mutations in 5 candidate genes discovered by targeted sequencing of cervical tumors. Supplementary Table 4. Association of HPV type and PIK3CA mutation. Supplementary Table 5. PIK3CA mutations in histologic subtype in this and other published studies Supplementary Table 6. Fig.3A_B_C raw data
Supplementary Figures 1-11 from Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
Authors: Lou Hong , Villagran Guillermo , Boland Joseph F. , Im Kate M. , Polo Sarita , Zhou Weiyin , Odey Ushie , Juárez-Torres Eligia , Medina-Martínez Ingrid , Roman-Basaure Edgar , Mitchell Jason , Roberson David , Sawitzke Julie , Garland Lisa , Rodríguez-Herrera Maria , Wells David , Troyer Jennifer , Pinto Francisco Castillo , Bass Sara , Zhang Xijun , Castillo Miriam , Gold Bert , Morales Hesler , Yeager Meredith , Berumen Jaime , Alvirez Enrique , Gharzouzi Eduardo , Dean Michael
Published: April 2023

Supplementary Figures 1-11. Supplementary Figure 1. Sample and analyses diagram. Supplementary Figure 2. Aggregate mutation spectrum of Guatemalan cervical tumors. Supplementary Figure 3. Highly amplified regions of chromosome (Chr.) 2, 6 and 10 in tumor A4. Supplementary Figure 4. Chromosome breakpoints in cervical tumors. Supplementary Figure 5. PIK3CA mutation and pathology. Supplementary Figure 6. Co-occurring mutations in the PIK3CA and PTEN genes. Supplementary Figure 7. Sanger sequence concordance of mutant read percentage. Supplementary Figure 8. Mutation Fraction of PIK3CA mutations. Supplementary Figure 9. Age range associations with PIK3CA mutation and HPV type. Supplementary Figure 10. PIK3CA and HPV E6 and E7 mRNA expression. Supplementary Figure 11. Model of cervical cancer progression.
Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 130KB, Clinicopathologic Characteristics in NSCLC Patients with FGFR, ALK, RET and ROS1 fusions.
Supplementary Table 1 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 81KB, Primers Used for Sequencing of FGFR Fusion.
Supplementary Figure 2 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Representative positive/negative expression of FGFR1 (A/B), FGFR3c(C/D),FGFR3a(E/F) in NSCLC
Supplemental Table 1-5 from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

Supplemental tables 1-5
Supplementary Figures S1-4 from A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Authors: Pandit-Taskar Neeta , O'Donoghue Joseph A. , Durack Jeremy C. , Lyashchenko Serge K. , Cheal Sarah M. , Beylergil Volkan , Lefkowitz Robert A. , Carrasquillo Jorge A. , Martinez Danny F. , Fung Alex Mak , Solomon Stephen B. , Gönen Mithat , Heller Glenn , Loda Massimo , Nanus David M. , Tagawa Scott T. , Feldman Jarett L. , Osborne Joseph R. , Lewis Jason S. , Reuter Victor E. , Weber Wolfgang A. , Bander Neil H. , Scher Howard I. , Larson Steven M. , Morris Michael J.
Published: April 2023

Supplementary Figures S1-4. Figure S1. 89Zr-J591 versus bone scan comparison of lesion positivity. Figure S2. Patient with metastatic prostate cancer (PSA of 10.1) with 89Zr-J591+ lesions that were not seen on MDP. Figure S3. Patient with metastatic prostate cancer (PSA of 0.62). Figure S4. Uniform prior distribution.
Supplementary Figure 1 from Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Authors: Apellániz-Ruiz María , Lee Mi-Young , Sánchez-Barroso Lara , Gutiérrez-Gutiérrez Gerardo , Calvo Isabel , García-Estévez Laura , Sereno María , García-Donás Jesús , Castelo Beatriz , Guerra Eva , Leandro-García Luis J. , Cascón Alberto , Johansson Inger , Robledo Mercedes , Ingelman-Sundberg Magnus , Rodríguez-Antona Cristina
Published: April 2023

Supplementary Figure 1. CYP3A4.25 protein stability assessment
Supplementary Figure 1. RET mediates GFRα1 effects in prostate cancer from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

A. Knockdown of RET mRNA by RET siRNA in LNCaP and 22RV1 cells. B-D. Effect of RET siRNA on GFRα1 induced proliferation (B), invasion (C) and soft agar colony formation (D). The p-values for significant differences by t-test are shown.
Supplementary Materials and Methods from Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Authors: Lundberg Arian , Lindström Linda S. , Harrell J. Chuck , Falato Claudette , Carlson Joseph W. , Wright Paul K. , Foukakis Theodoros , Perou Charles M. , Czene Kamila , Bergh Jonas , Tobin Nicholas P.
Published: April 2023

All supplementary materials and methods
Supplementary table 1 from Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Authors: Yakirevich Evgeny , Resnick Murray B. , Mangray Shamlal , Wheeler Michael , Jackson Cynthia L. , Lombardo Kara A. , Lee Jeeyun , Kim Kyoung-Mee , Gill Anthony J. , Wang Kai , Gowen Kyle , Sun James , Miller Vincent A. , Stephens Philip J. , Ali Siraj M. , Ross Jeffrey S. , Safran Howard
Published: April 2023

Previously reported cases of colorectal carcinoma harboring ALK fusions
Supplementary Figures S1-6 from Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Authors: Lundberg Arian , Lindström Linda S. , Harrell J. Chuck , Falato Claudette , Carlson Joseph W. , Wright Paul K. , Foukakis Theodoros , Perou Charles M. , Czene Kamila , Bergh Jonas , Tobin Nicholas P.
Published: April 2023

Supplementary figure S1: Survival analysis (Kaplan-Meier estimates) with Breast cancer specific survival (BCSS) as end point for All patients of Cohort 1. Supplementary figure S2: Flowchart showing simplified results from Cohort 1. Supplementary figure S3: Additional prognostic value of gene expression signatures beyond Ki67/IHC, Cohort 1. Supplementary figure S4: Additional prognostic value of Ki67/IHC beyond gene expression signatures, Cohort 1. Supplementary figure S5: Additional prognostic value of gene expression signatures beyond Ki67/IHC, Cohort 2. Supplementary figure S6: Additional prognostic value of Ki67/IHC beyond gene expression signatures, Cohort 2.
Video S1 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Video made with the laparoscopic fluorescence camera during experiment #1.
Figure S2 from Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma
Authors: Iida Yuuki , Ciechanover Aaron , Marzese Diego M. , Hata Keisuke , Bustos Matias , Ono Shigeshi , Wang Jinhua , Salomon Matthew P. , Tran Kevin , Lam Stella , Hsu Sandy , Nelson Nellie , Kravtsova-Ivantsiv Yelena , Mills Gordon B. , Davies Michael A. , Hoon Dave S.B.
Published: April 2023

TIFF file for supplementary figure S2
Supplementary Table S6 from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Oncotype Dx recurrence scores and clinical outcome for all patients
Figure S1 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Schematic overview of the different steps of the perfusion experiment.
Supplementary Table S5 from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Sample type correlations among genes that show moderate to high intra-tumor heterogeneity
Supplementary Table 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Overview of factors, cut-offs, and analysis of overall survival according to cohorts
Supplementary Table 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Patients treated with pembrolizumab according to clinical site
Suppl Fig 1 from Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Authors: Subbiah Vivek , Grilley-Olson Juneko E. , Combest Austin J. , Sharma Neelesh , Tran Richard H. , Bobe Iulian , Osada Atsushi , Takahashi Kazuhiro , Balkissoon Jaikrishna , Camp Aaron , Masada Atsuhiro , Reitsma Dirk J. , Bazhenova Lyudmila A.
Published: April 2023

EORTC QLQ-C30
Supplementary Figure 4 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Alternative combination models according for the relative impact of LDH, REC, RLC and the pattern of visceral metastasis. A nomogram was developed using the nomogram function of R (A). For each patient a linear predictor score (risk score) considering the relative impact of four single factors was calculated as follows: LDH-ratio >2.5 - 100 points; presence of visceral metastasis other than lung - 96 points; REC <1.5% - 69 points; RLC <17.5% - 68 points. Thus, the resulting risk score (RS) ranges between 0 and 333 points. Kaplan-Meier analysis of overall survival is presented for 5 different combination models according to different risk score category definitions (B - E). Censoring is indicated by vertical lines. The discriminatory abilities (c-indices) for the respective models were 0.780 (B), 0.779 (C), 0.782 (D), 0.785 (E), and 0.781 (F).
Supplementary Figure 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Overall survival according to the relative lymphocyte and eosinophil counts in 3 subgroups of patients defined by LDH and the pattern of visceral metastasis. Kaplan Meier curves for OS are presented according to relative lymphocyte count (left), relative eosinophil counts (middle) and the count of favorable pre-treatment values considering both factors (right). In patients 132 patients with LDH-ratio {less than or equal to}2.5 AND no visceral metastasis other than lung (A) OS was significantly longer in patients with RLC {greater than or equal to}17.5% (p=0.003) and in those with 2 vs 0 favorable pretreatment values (p=0.022). In 310 patients with either LDH-ratio {less than or equal to}2.5 OR no visceral metastasis other than lung (B) OS was significantly in all pairwise comparisons of the three biomarker categories (all log rank p<0.001). In 70 patients with LDH-ratio >2.5 AND visceral metastasis other than lung (C) the differences in OS between patients with 2 vs 0 favorable pretreatment factors was not statistically significant (log rank p=0.108).